MREO Stock Forecast & Price Target

Mereo BioPharma Group is a promising U.K. based biopharmaceutical company that has developed a portfolio of late-stage clinical product candidates focused on rare diseases, including setrusumab for OI and alvelestat for AATD-LD. Although the Orbit study missed its primary endpoint of AFR, a median AFR of 0 in the placebo arm is notable and the Cosmic study showed a lower incidence of vertebral fractures with setrusumab. The company faces typical risks of development stage biotech companies, but positive BMD improvements and favorable fracture trends in the Cosmic study could support a path to market.

Mereo BioPharma Group is facing significant challenges as they await results from their late-stage clinical trials for their two rare disease product candidates. Leaks of data from the trials reveal underwhelming results, and the company's valuation is heavily reliant on the success of these programs, leaving room for potential negative impact on future revenue. In addition, the company faces standard risks for the industry, including unexpected outcomes from trials and uncertainty in regulatory approval and commercial markets.